Amber Hestla

Amber Hestla is Lead Investment Strategist behind Profitable Trading's Income Trader, Profit Amplifier and Maximum Income. She specializes in generating income using options strategies that minimize risk by applying skills she learned on military deployments and intelligence training to the markets.

While deployed overseas with the military, Amber learned the importance of analyzing data to forecast what is likely to happen in the future, a skill she now applies to financial markets. Prior to that, Amber studied risk management working undercover. While risk management is no longer a matter of life and death, she believes it is the most important factor in long-term trading success.

And although she makes her living in the markets, she continues to study the markets and trading daily. Her writing has been featured in trading magazines including the Market Technicians Association newsletter, Technical Analysis of Stocks & Commodities and Stocks, Futures and Options in the United States, and Shares, a weekly trading magazine published in the United Kingdom.

Analyst Articles

Among the biggest winners in Friday’s early trading are Smith & Wesson (Nasdaq: SWHC) and Cooper Cos. (NYSE: COO).   Soon after President Obama took office, gun sellers did a brisk amount of business on fears that firearms laws would soon become more restrictive. This chart of… Read More

As you can see below, the CurrencyShares Euro Trust (NYSE: FXE) fell from $134 in March to $120 in August. A recovery to the halfway point of that decline at $127 would likely send desperate short sellers running for cover. A larger objective targets a move above $130. Read More

It’s often said that what is past is prologue, and that’s usually true when it comes to financial markets. And when we look at past performance for the markets in September, we get a gloomy sense of prologue. That’s because, historically, September is the worst-performing month of the year for… Read More

When it comes to investing biotech stocks, it’s wise to focus on companies that have completed much of their drug development work. The closer a company gets to the finish line in the clinical-testing process, the less chance that a drug will fail — taking the company’s stock down sharply.#-ad_banner-#… Read More